ALEXANDRIA, Va., March 31 -- United States Patent no. 12,590,147, issued on March 31, was assigned to OBLIQUE THERAPEUTICS AB (Gothenburg, Sweden).
"TRPV1 epitopes and antibodies" was invented by Carolina Trkulja (Hokerum, Sweden), Max Davidson (Gothenburg, Sweden) and Owe Orwar (Hovas, Sweden).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to antibodies that bind to TRPV1. The invention also relates to certain epitopes of the protein TRPV1. The invention also relates to immunoconjugates and compositions comprising such antibodies. The invention also provides methods of producing such antibodies. The invention further provides the use of such antibodies for therapeutic purposes, ...